Pregled bibliografske jedinice broj: 538267
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization // American journal of hematology, 86 (2011), 7; 550-553 doi:10.1002/ajh.22038 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 538267 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization
Autori
Basak, Grzegorz W. ; Jakšić, Ozren ; Koristek, Zdenek ; Mikala, Gabor ; Mayer, Jiri ; Masszi, Tamas ; Labar, Boris ; Wiktor-Jedrzejczak, Wieslaw
Izvornik
American journal of hematology (0361-8609) 86
(2011), 7;
550-553
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
plerixafor
Sažetak
The introduction of plerixafor has enabled successful collection of stem cells in the majority of patients with lymphoma or myeloma in whom previous attempts at mobilization have failed. However, a proportion of patients have been shown to be resistant to this mobilization regimen. To identify the factors that impair stem cell mobilization and collection with plerixafor, we reviewed the data for 197 patients who had undergone mobilization with plerixafor and granulocyte-colony stimulating factor in Central Europe. Predictors of mobilization failure were evaluated using logistic regression analysis. Among the 197 patients mobilized, the target of >2.0 x 10(6) CD34+ cells/kg was collected from 133 (67.5%). Our analysis revealed that previous treatment with lenalidomide, bortezomib, melphalan, radiotherapy, or autologous stem cell transplantation and regimen of plerixafor use in combination with chemotherapy had no significant effect on the efficiency of collection. In contrast, an age >= 65 years (odds ratio 0.331, 95% CI: 0.112-0.977, P < 0.05), a diagnosis of non-Hodgkin's lymphoma (odds ratio 0.277, 95% CI: 0.124-0.622, P < 0.01), and treatment with >= four chemotherapy regimens (odds ratio 0.366, 95% CI: 0.167-0.799, P < 0.05) were associated significantly with failed mobilization. The rate of successful mobilizations was decreased in patients treated with purine analogues (odds ratio 0.323, 95% CI: 0.096-1.094, P = 0.07) but increased in female patients (odds ratio 1.961, CI: 0.943-4.080, P = 0.07). Patients who are characterized by the above negative features could benefit potentially from further improvement in the mobilization strategy. Am. J. Hematol. 86:550- 553, 2011. (C) 2011 Wiley-Liss, Inc.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
198-1980955-0953 - Imunobiologija kronične B-limfocitne leukemije i mikrookoliš (Jakšić, Ozren, MZOS ) ( CroRIS)
Ustanove:
Klinička bolnica "Dubrava",
Klinički bolnički centar Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE